Drugs in the Pipeline
Study: Longer Overall Survival for Keytruda vs. Docetaxel
Merck announced that the KEYNOTE-010 study of Keytruda (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) met its primary endpoint.
Your search for non small cell lung cancer returned 493 results
Drugs in the Pipeline
PARP Inhibitor Veliparib Gets Orphan Drug Status from FDA
AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Positive Outcomes Observed with Xalkori in NSCLC Study
Pfizer announced results from PROFILE 1014, a Phase 3 study of Xalkori (crizotinib) in previously untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC).
Generics News
Dr. Reddy’s Launches Generic Taxotere
Dr. Reddy's Laboratories announced the launch of Docetaxel Injection, the generic version of
Sanofi Aventis' Taxotere.
Drugs in the Pipeline
Atezolizumab Gets Priority Review as Adjuvant Treatment for Early NSCLC
The sBLA is supported by data from the IMpower010 study that compared atezolizumab with best supportive care in 1005 adults with Stage IB-IIIA NSCLC after resection and adjuvant chemotherapy.
Drugs in the Pipeline
Patritumab Deruxtecan Gets Breakthrough Tx Status for Metastatic EGFR-Mutated NSCLC
Patritumab deruxtecan consists of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
Drugs in the Pipeline
AbbVie Launches Veliparib Trial for NSCLC
AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Drug News
Demographic Variation in Early PET Scan Use for Lung Cancer
For Medicare beneficiaries with non-small-cell lung cancer, demographic differences in the rates of positron emission tomography scan use persisted from 1998 to 2007.
News
New Targeted Tx for Metastatic NSCLC Launched
AstraZeneca announced the launch of Tagrisso (osimertinib) for treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).
Drug News
Molecular Differences ID’d for Small/Non-Small Cell Lung CA
Molecular differences have been identified in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cell lines, which may represent potential therapeutic targets.
